Navigation Links
Genzyme Reports Strong First-Quarter Growth

Non-GAAP EPS Increased 22 Percent

CAMBRIDGE, Mass., April 23 /PRNewswire-FirstCall/ -- Genzyme Corporation (Nasdaq: GENZ) today reported results for the first quarter of 2008, which featured excellent revenue growth, continued operating leverage, a significant increase in non-GAAP profit, and strong progress across the company.

First-Quarter Highlights

-- Total revenue for the quarter grew 25 percent to $1.1 billion from

$883.2 million in same period a year ago. This increase was driven by

growth across all product lines, led by strong growth in sales of

treatments for lysosomal storage disorders and renal disease.

Genzyme's top line now includes sales of Aldurazyme(R) (laronidase),

which previously were recorded as joint venture revenue.

-- GAAP net income in the first quarter was $145.3 million, or $0.52 per

diluted share, compared with $158.2 million, or $0.57 per diluted

share. GAAP net income in this year's first quarter reflects an after-

tax charge of $56.5 million for the premium related to Genzyme's

strategic investment in Isis Pharmaceuticals Inc.

-- Non-GAAP net income increased 24 percent to $260.9 million, compared

with $210.7 million in the first quarter a year earlier. Non-GAAP

earnings increased 22 percent to $0.95 per diluted share from $0.78 per

diluted share in the first quarter last year.

-- Non-GAAP operating expenses decreased as a percentage of revenue,

reflecting global operating leverage.

-- Genzyme continued to generate significant cash from operations and to

reinvest in the future of the company. In the first quarzyme produced at the 2000L capacity and the timing thereof; its plans to seek regulatory approvals of existing products for use in new indications, including Renvela for CKD, the timetables therefore and the impact of such approvals on the company; its plans and estimated timetables for new and next- generation product filings, regulatory actions and launches, including for Mozobil, Clolar, alemtuzumab-MS, mipomersen, Genz-112638 and Synvisc-ONE and the assessment of the market potential of such products; its projected Myozyme revenues for 2008; and its anticipated growth drivers for certain products and businesses, including Genetics and Thymoglobulin. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those forecasted. These risks and uncertainties include, among others: Genzyme's ability to successfully complete preclinical and clinical development of its products and product candidates, including Mozobil, Clolar, alemtuzumab-MS, mipomersen, and Genz-112638; Genzyme's ability to expand the use of current and next-generation products in existing and new indications, including Renvela and Synvisc-ONE; Genzyme's ability to obtain and maintain regulatory approvals for products and manufacturing facilities, including Myozyme produced at the 2000L scale in the US and at the 4000L scale in Europe and the timing of receipt of such approvals; Genzyme's ability to manufacture its products, including Thymoglobulin and its LSD therapies in a timely and cost effective manner and in sufficient quantities to meet demand; and the risks and uncertainties described in Genzyme's SEC reports filed under the Securities Exchange Act of 1934, including the factors discussed under the caption "Risk Factors" in Genzyme's 2007 Annual Report on Form 10-K. Genzyme cautions investors not to place substantial reliance on the forward-looking statements contained in this press release. These statements speak only as of today's date and Genzyme undertakes no obligation to update or revise the statements.

Genzyme(R), Myozyme(R), Fabrazyme(R), Cerezyme(R), Thyrogen(R), Renagel(R), Renvela(R), Thymoglobulin(R), Synvisc(R), Campath(R) and Clolar(R) are registered trademarks of and Mozobil(TM) and Synvisc-ONE(TM) are unregistered trademarks of Genzyme or its subsidiaries. Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC. All rights reserved.

About Genzyme

One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 10,000 employees in locations spanning the globe and 2007 revenues of $3.8 billion. In 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation.

With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as immune disease, cardiovascular disease, and other areas of unmet medical need.

Conference Call Information

Genzyme will host a conference call today at 11:00 a.m. Eastern to discuss results for the first quarter of 2008. To participate in the call, please dial 773-799-3828 and refer to pass code "Genzyme." A replay of this call will be available by dialing 402-998-1342. This call will also be Webcast live on the investor events section of Replays of the call and the Webcast will be available until midnight April 30, 2008.

Upcoming Events

Genzyme will host a conference call on July 23, 2008 at 11:00 a.m. Eastern to discuss financial results for the second quarter of 2008. To participate in the call, please dial 773-799-3828 and refer to pass code "Genzyme." A replay of this call will be available by dialing 402-998-1342. This call will also be Webcast live on the investor events section of Replays of the call and the Webcast will be available until midnight on July 30, 2008.

Genzyme's press releases and other company information are available at and by calling Genzyme's investor information line at 1-800-905-4369 within the United States or 1-678-999-4572 outside the United States.

Media Contact: Investor Contact:

Bo Piela Patrick Flanigan

(617) 768-6579 (617) 768-6563


Consolidated Statements of Operations

(Unaudited, amounts in thousands, Three Months Ended

except per share amounts) March 31,

2008 2007

Total revenues $1,100,061 $883,183

Operating costs and expenses:

Cost of products and services sold (1) 272,313 202,463

Selling, general and administrative (1) 318,386 269,021

Research and development (1,2) 262,797 166,120

Amortization of intangibles 55,658 50,017

Total operating costs and expenses 909,154 687,621

Operating income (loss) 190,907 195,562

Other income (expenses):

Equity in income of equity method

investments 188 5,612

Minority interest 463 3,912

Gain (loss) on investments in

equity securities (3) 775 12,788

Other (160) (525)

Investment income 14,870 16,219

Interest expense (1,655) (4,188)

Total other income (expenses) 14,481 33,818

Income (loss) before income taxes (1) 205,388 229,380

(Provision for) benefit from income

taxes (1) (60,117) (71,193)

Net income (loss) (1) $145,271 $158,187

Net income (loss) per share:

Basic $0.54 $0.60

Diluted (1,4) $0.52 $0.57

Weighted average shares outstanding:

Basic 267,276 263,476

Diluted (1,4) 285,208 279,924

(1) In accordance with the provisions of Financial Accounting Standards

Board, or FASB, Statement of Financial Accounting Standards No., or

FAS, 123R, "Share-Based Payment, an amendment of FASB Statement Nos.

123 and 95," we recorded pre-tax charges for stock-based compensation

expense and related tax benefits of:

Three Months Ended

March 31,

2008 2007

Cost of products and services sold $(6,514) $(5,896)

Selling, general and administrative

expense (22,889) (22,499)

Research and development expense (12,585) (12,312)

Total pre-tax charges for stock-

based compensation expense (41,988) (40,707)

Tax benefit 12,537 12,432

Stock-based compensation expense,

net of tax $(29,451) $(28,275)

Diluted earnings per share and diluted weighted average shares outstanding

for the three months ended March 31, 2008 and 2007 were computed according

to the provisions of FAS 123R.

(2) Includes a charge of $(69,900)K recorded in February 2008 representing

the premium paid to purchase five million shares of Isis

Pharmaceuticals, Inc. common stock.

(3) For the three months ended March 31, 2007, includes a pre-tax gain of

$10,848K related to the sale of our entire investment in the common

stock of Therapeutic Human Polyclonals, Inc. in March 2007, which had

a zero cost basis.

(4) All periods reflect the adoption of Emerging Issues Task Force Issue

No. 04-8, "The Effect of Contingently Convertible Debt on Diluted

Earnings Per Share," or EITF 04-8. As a result of the adoption of EITF

04-8, the 9,686K shares issuable upon conversion of our $690.0 million

in principal of 1.25% convertible senior notes, which were issued in

December 2003, are now included in diluted weighted average shares

outstanding for purposes of computing diluted earnings per share,

unless the effect would be anti-dilutive. In accordance with EITF 04-

8, interest and debt fees related to these notes of $1.9 million, net

of tax, for both the three months ended March 31, 2008 and 2007, have

been added back to net income and 9,686K shares have been added to

diluted weighted average shares outstanding for both of these periods

for purposes of computing diluted earnings per share.


Condensed Consolidated Balance Sheets March 31, December 31,

(Unaudited, amounts in thousands) 2008 2007

Cash and all marketable securities $1,447,983 $1,460,394

Other current assets 1,818,541 1,661,740

Property, plant and equipment, net 2,118,960 1,968,402

Intangibles, net (1) 3,386,451 2,959,480

Other assets (2) 311,581 251,725

Total assets $9,083,516 $8,301,741

Current liabilities $1,475,663 $1,502,406

Noncurrent liabilities (1) 658,936 186,398

Stockholders' equity 6,948,917 6,612,937

Total liabilities and stockholders'

equity $9,083,516 $8,301,741

(1) Effective January 1, 2008, in connection with the restructuring of

BioMarin/Genzyme LLC, our joint venture with BioMarin Pharmaceutical

Inc., we licensed certain rights to commercialize Aldurazyme from the

joint venture and, in accordance with the provisions of FASB

Interpretation No. 46R, "Consolidation of Variable Interest Entities,"

began consolidating the results of the joint venture at fair value. As

of March 31, 2008, intangibles, net, includes $480,500K for the fair

value of the joint venture's manufacturing and commercialization

rights to Aldurazyme, offset by $(6,006)K of related accumulated

amortization. Noncurrent liabilities includes $474,494K of additional

net liabilities related to the fair value of these rights. Excluding

these rights, the fair values of the assets and liabilities of the

joint venture as of March 31, 2008 were not significant.

(2) As of March 31, 2008, Other assets includes $80,100K for the fair

value of the five million shares of Isis Pharmaceuticals, Inc. common

stock that we purchased in February 2008.



For the Three Months Ended March 31, 2008

(Amounts in thousands, except per share data)


Due to Premium on

Common Stock Strategic Equity

NON-GAAP Equivalents Investment

Income Statement


Total revenues $1,100,061

Cost of products

and services sold $(265,799)

Selling, general and

administrative $(295,497)

Research and development $(180,312) $(69,900)

Amortization of

intangibles $-

Equity in income (loss)

of equity method

investments $188

Minority interest $463

Gains (losses) on

investments in equity

securities $775

Other $(160)

Investment income $14,870

Interest expense $(1,655)


Income (loss) before

income taxes $372,934 $- $(69,900)

(Provision for) benefit

from income taxes $(112,039) $- $13,428

Net income (loss) $260,895 $- $(56,472)

Net income (loss)

per share:

Basic $0.98 $- $(0.21)

Diluted (1) $0.95 $(0.03) $(0.20)

Weighted average

shares outstanding:

Basic 267,276

Diluted (1) 275,522 9,686


Amortization Expense Reported

Income Statement


Total revenues $1,100,061

Cost of products

and services sold $(6,514) $(272,313)

Selling, general

and administrative $(22,889) $(318,386)

Research and development $(12,585) $(262,797)

Amortization of

intangibles $(55,658) $(55,658)

Equity in income (loss)

of equity method investments $188

Minority interest $463

Gains (losses) on investments

in equity securities $775

Other $(160)

Investment income $14,870

Interest expense $(1,655)


Income (loss) before income

taxes $(55,658) $(41,988) $205,388

(Provision for) benefit

from income taxes $25,957 $12,537 $(60,117)

Net income (loss) $(29,701) $(29,451) $145,271

Net income (loss) per share:

Basic $(0.11) $(0.12) $0.54

Diluted (1) $(0.10) $(0.10) $0.52

Weighted average shares


Basic 267,276

Diluted (1) 285,208

(1) GAAP As-Reported diluted earnings per share and diluted weighted

average shares outstanding reflect the adoption of EITF 04-8. In

accordance with the provisions of EITF 04-8, interest and debt fees

related to our 1.25% convertible senior notes of $1,886K, net of tax,

have been added back to net income and approximately 9,686K shares

have been added to diluted weighted average shares for purposes of

computing GAAP As-Reported diluted earnings per share.


April 21, 2008 Guidance


Renagel / Renvela $690 $700

Total Renal 800 815

Cerezyme 1,215 1,240

Fabrazyme 495 505

Myozyme 275 285

Aldurazyme 135 145

Total Therapeutics 2,325 2,385

Total Transplant 210 220

Synvisc 270 280

Total Biosurgery 490 505

Total Diag/Genetics 475 485

Total Other 260 270

TOTAL REVENUE $4,450 $4,650

**GROSS MARGIN approx. 77%

**SG&A approx. 27%

**R&D approx. 17%

Net Interest / Other approx. 60

TAX RATE - GAAP approx. 30%

*TAX RATE - NON-GAAP approx. 31%

GENZ GAAP EPS approx. $2.65

AMORTIZATION approx. $0.55

FAS123 EXPENSE approx. $0.60



***WTD AVERAGE SHARES O/S approx. 274


This financial guidance, which is provided as part of a press release

dated April 21, 2008, is subject to all of the qualifications and

limitations described therein. Actual results may differ from these

forward-looking statements due to the numerous factors described in the

press release.

* Non-GAAP tax rate excludes the impact of amortization, one-time events,

FAS123R expense and EITF 04-8.

**Non-GAAP excludes the impact of amortization, one-time events, FAS123R

expense and EITF 04-8.

***WTD Average Shares Outstanding excludes the impact of EITF 04-8.

ter, Genzyme

generated approximately $373 million in cash from net income prior to

one-time events and proceeds from the issuance of common stock. The

company invested approximately $122 million in capital projects to

expand manufacturing capacity to meet current and anticipated product

demand. The company also made a $150 million investment in Isis

Pharmaceuticals associated with the license of mipomersen, a highly

promising product candidate in late-stage development.

-- Genzyme is also using a portion of its operating cash flow to

repurchase shares under a three-year program to reduce the dilutive

effect of equity compensation. The company repurchased 1 million

shares in the first quarter and has repurchased approximately 4.5

million shares since this program began one year ago.

"We had a very strong first quarter to start the year," said Henri A. Termeer, Genzyme's chairman and chief executive officer. "We continue to focus on our commitment to deliver 20 percent non-GAAP earnings growth through 2011, while building the company to ensure that we sustain our growth over the longer term."

Financial Guidance

-- Genzyme expects 2008 non-GAAP earnings of approximately $3.90 per

diluted share, compared with prior guidance of $4.00 per diluted share.

This previously announced adjustment reflects the delay in FDA approval

of 2000L production capacity for Myozyme.

-- GAAP earnings in 2008 are expected to be approximately $2.65 per

diluted share, compared with prior guidance of approximately $2.75 per

diluted share. GAAP figures include anticipated amortization and

stock-compensation expenses and the effect of contingent convertible


-- Genzyme reaffirmed its commitment to 20 percent growth in compound non-

GAAP earnings per share through 2011. Non-GAAP earnings are projected

to rise to approximately $7.00 per diluted share by 2011.

-- Myozyme sales are expected to be approximately $275-$285 million this

year, compared to prior guidance of $320-$330 million.

-- Non-GAAP earnings per share for the second quarter are expected to be

in the mid $0.90s, reflecting ongoing investments to drive future

growth. These include investments in the U.S. launch of Renvela(R)

(sevelamer carbonate) and the expanded European introduction of

Clolar(R) (clofarabine), as well as investments in late-stage clinical

trials-particularly the phase 3 study of alemtuzumab for multiple

sclerosis. This estimate also reflects the constraints on U.S. Myozyme


First-Quarter Product Sales

-- Within the Therapeutics business, worldwide demand for Myozyme remains

robust two years into the product's launch. First-quarter sales rose

78 percent despite the delay in U.S. approval for 2000L production

capacity. Sales increased to $67.3 million from $37.9 million in the

period a year ago, driven by the number of new patients starting

therapy. As announced, the FDA will require Genzyme to submit a BLA to

obtain U.S. commercial approval for Myozyme produced at the 2000L

scale. The agency is expected to act on the application by the end of

this year.

-- First-quarter sales of Cerezyme(R) (imiglucerase for injection) rose 15

percent to $304.3 million, compared with $263.8 million in the previous

first quarter.

-- Sales of Fabrazyme(R) (agalsidase beta) grew 16 percent in the quarter,

rising to $116.5 million from $100.7 million in the first quarter last

year. Fabrazyme has captured more than a two thirds share of the

international market for Fabry disease treatment based on compelling

clinical data and an established global regulatory and commercial


-- Sales of Aldurazyme(R) (laronidase) increased 38 percent to $37.0

million in the first quarter, compared with $26.8 million in the same

quarter a year ago. Genzyme now records sales of Aldurazyme on its top

line and makes tiered payments to BioMarin Pharmaceutical Inc. on

worldwide product sales under a restructured agreement between the


-- Sales of Thyrogen(R) (thyrotropin alfa for injection) grew 28 percent

in the first quarter to $33.8 million from $26.3 million, reflecting

ongoing improvement in thyroid cancer detection and well-established

treatment guidelines. The use of Thyrogen in ablation procedures is

also contributing to the product's growth, following the December 2007

U.S. approval for this indication.

-- Within the Renal business, sales of sevelamer therapies Renagel(R)

(sevelamer hydrochloride) and Renvela grew 23 percent to $168.7 million

from $137.4 million in the first quarter last year. In March, Genzyme

launched Renvela in the United States, where the company is engaged in

active discussions with the FDA to expand the product's labeling to

include chronic kidney disease patients with hyperphosphatemia who are

not on dialysis. The three companies that currently market phosphate

binders are working collaboratively to provide the FDA with information

that will help the agency determine the appropriate treatment paradigm

for these patients. Genzyme anticipates that the Renvela label

expansion will take place at the latest by the middle of 2009. Genzyme

has also filed for European approval for Renvela in both the dialysis

and chronic kidney disease indications.

-- Within the Transplant business, first-quarter sales of Thymoglobulin(R)

(Anti-thymocyte Globulin [Rabbit]) and Lymphoglobuline(R) (Anti-

thymocyte Globulin [Equine]) rose 11 percent to $43.7 million from

$39.4 million. Worldwide demand for Thymoglobulin remains strong. The

product's growth over the past several quarters has been hindered by

supply constraints caused by a manufacturing issue during 2007 that

affected product appearance in some lots. Genzyme instituted a

procedure at its French manufacturing plant at the end of last year

that resolved this manufacturing issue. The company continues to

monitor Thymoglobulin lots produced last year and, if necessary, will

recall any lots that are expected to go out of specification prior to

the originally established expiry period. Genzyme expects

Thymoglobulin sales to accelerate in the second-half of this year as

supply levels increase to meet full demand for the product.

-- Within the Biosurgery business, sales of Synvisc(R) (hylan G-F 20) and

Synvisc-ONE(TM) (hylan G-F 20) rose to $56.1 million from $53.6

million, an increase of 5 percent. Synvisc-One received CE Mark

approval in the European Union in December, and Genzyme is preparing to

introduce the product into the marketplace, where it will be the only

treatment of its kind to provide six months of pain relief with a

single injection. The company has already launched the product in the

United Kingdom, Germany and Italy. Genzyme will pursue marketing

approvals for Synvisc-One in Canada, Asia and Latin America based on

the European CE mark approval, and FDA action on a marketing

application in the United States is expected later this year. By

simplifying osteoarthritis pain management and thereby reaching a

broader set of patients, Synvisc-ONE is expected to drive the

significant growth of this product franchise.

-- Sales of Sepra(R) products continued to be strong, rising 32 percent to

$30.6 million in the first quarter from $23.1 million in the same

quarter a year ago. The expanded U.S. sales force for Seprafilm(R)

adhesion barrier is reaching a broader range of physicians and helping

drive the product's growth in gynecologic and colorectal surgery.

Future growth of the product in C-section procedures and trauma

surgeries is expected.

-- First-quarter revenue for the Genetics business increased 12 percent to

$74.3 million from $66.2 million, fueled substantially by a higher

volume of reproductive diagnostic testing. The profitability of the

Genetics business is also increasing through improvements in operating

efficiencies, while Genzyme continues to invest in additional

information technology and infrastructure to strengthen the competitive

advantages the business has created. Genzyme Genetics recently

launched carrier and prenatal diagnostic testing for spinal muscular

atrophy, the most common inherited cause of infant mortality. These

tests are expected to support continued profitable growth in subsequent


-- Oncology revenue increased 29 percent in the first quarter to $29.0

million from $22.4 million. This growth primarily reflects the

addition of European sales of Clolar, which Genzyme began recording

following its acquisition of Bioenvision Inc. late last year. Genzyme

is working to introduce Clolar worldwide through its global commercial

and regulatory organization. Oncology revenue also reflects growing

first-line use of Campath(R) (alemtuzumab) in the treatment of patients

with B-cell chronic lymphocytic leukemia.

Late-State Development Programs

Genzyme continues to make strong progress in advancing programs within its late-stage development pipeline. These programs have significant potential to drive the company's growth beyond 2011.

Mozobil(TM) (plerixafor) for stem-cell transplantation

-- Genzyme plans to file mid year for U.S. and European approval for

Mozobil's use in treating patients with multiple myeloma and patients

with lymphoma. The company expects to launch the product in the United

States early next year upon approval and to rapidly expand the

product's availability around the world. The company anticipates peak

annual sales of the product in the transplant setting of $400 million.

Mozobil is an innovative product intended to enhance the mobilization

of stem cells for transplantation in patients with lymphoma and

multiple myeloma. In two pivotal clinical studies, Mozobil showed the

ability to quickly and predictably prepare cancer patients for a

transplant to treat their disease. Genzyme is also exploring

additional indications for Mozobil, including its potential use in

chemosensitization procedures.

Clolar for adult AML

-- Clolar is approved in the United States and Europe for the treatment of

acute lymphoblastic leukemia in relapsed and refractory pediatric

patients. Genzyme is developing the product for use globally as a

first-line therapy for the treatment of adult acute myeloid leukemia

(AML) and myelodysplastic syndromes, significantly larger indications

that the company estimates will drive peak annual sales of the product

to approximately $600 million. The company intends to submit a

supplemental new drug application in the United States later this year

to include an adult AML indication. This application will be based on

results from the CLASSIC II clinical trial involving older adult AML

patients. Preliminary data from this trial will be presented at the

American Society of Clinical Oncology meeting in June.

Genzyme is developing a new filing for the adult AML indication in

Europe. This follows its withdrawal of Bioenvision's marketing

application, which, as expected, an advisory committee deemed

insufficient to support approval. Genzyme expects to make a new

submission as early as the fourth quarter of this year that will

include a more robust data package from Genzyme sponsored studies.

Alemtuzumab for multiple sclerosis

-- Final, three-year efficacy and safety data from the Phase 2 trial

comparing alemtuzumab with Rebif (interferon beta-1a) for the treatment

of relapsing-remitting multiple sclerosis were presented last week

during a scientific platform session at the American Academy of

Neurology meeting by Dr. Alasdair Coles. These results confirm all

trends observed in the one- and two-year interim analyses. The two

ongoing Phase 3 trials further examining the efficacy and safety of

alemtuzumab for the treatment of MS are progressing. These two studies

are currently enrolling patients at sites in the United States, Europe,

Latin America and Australia. Genzyme believes that alemtuzumab has the

potential to be the best therapy in a market for MS drugs that is

projected to reach $8-9 billion annually when the treatment is expected

to be ready for launch in 2011-2012. Alemtuzumab is being developed in

collaboration with Bayer Schering Pharma AG, Germany.

Genz-112638 for Gaucher disease

-- Genzyme is making excellent progress in developing the small molecule

Genz-112638, a novel oral therapy intended for the treatment of Gaucher

disease. Initial results released one year ago for the first group of

study participants were encouraging. Genzyme expects to release

results by mid year for a larger number of patients, including results

for those patients who have completed the one year trial. Final

results for all trial participants will be available in the first

quarter of 2009. Genzyme is currently developing clinical trial

protocols for two Phase 3 studies of Genz-112638, and the company

anticipates initiating these studies early next year. Genzyme believes

that this oral product may offer a more convenient treatment option for

some patients.

Mipomersen for high-risk cardiovascular disease

Genzyme expects to finalize its license of mipomersen from Isis

Pharmaceuticals in the second quarter and subsequently communicate a

development plan for the product. Mipomersen is a lipid-lowering agent

being developed primarily for patients at significant cardiovascular

risk who are unable to achieve target cholesterol levels with statins

alone or who are intolerant of statins. The product offers an

innovative approach to addressing a serious unmet medical need, and

Genzyme believes it could prove to be the most effective lipid-lowering

agent for high risk cardiovascular disease patients for whom

conventional therapies are not sufficient. The product may provide

significant benefit over the standard of care and targets a well-defined

and severely ill patient population. Mipomersen is currently being

studied in a Phase 3 clinical trial involving patients with homozygous

familial hypercholesterolemia.

This press release contains forward-looking statements regarding Genzyme's financial outlook and business plans and strategies, including without limitation: its Q2 2008, YE 2008 and YE 20011 earnings guidance; its anticipated CAGR through 2011; its expectations for approval of Myo

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Genzyme to Build New R&D Center in Beijing
2. Genzyme Provides Update on Myozyme(R) Manufacturing
3. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
4. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
5. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
6. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
7. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
8. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
9. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
10. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
11. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
Post Your Comments:
(Date:10/11/2017)... ... 11, 2017 , ... Singh Biotechnology today announced that the ... its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) B VHH13 single ... the cell membrane and bind intracellular STAT3 and inhibit its function. Dysregulation of ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give it ... Nanoparticle), a technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). ...
(Date:10/10/2017)... ... 2017 , ... Dr. Bob Harman, founder and CEO of VetStem Biopharma, ... The event entitled “Stem Cells and Their Regenerative Powers,” was held on ... DVM, MPVM was joined by two human doctors: Peter B. Hanson, M.D., Chief of ...
(Date:10/10/2017)... CRUZ, Calif. , Oct. 10, 2017 ... grant from the NIH to develop RealSeq®-SC (Single Cell), ... kit for profiling small RNAs (including microRNAs) from single ... Analysis Program highlights the need to accelerate development of ... "New techniques for measuring ...
Breaking Biology Technology:
(Date:4/18/2017)... 2017  Socionext Inc., a global expert in SoC-based imaging and ... the M820, which features the company,s hybrid codec technology. A demonstration ... Probe, Inc., will be showcased during the upcoming Medtec Japan at ... the Las Vegas Convention Center April 24-27. ... Click here for an ...
(Date:4/13/2017)... April 13, 2017 UBM,s Advanced Design and ... will feature emerging and evolving technology through its 3D ... will run alongside the expo portion of the event ... and demonstrations focused on trending topics within 3D printing ... and manufacturing event will take place June 13-15, 2017 at ...
(Date:4/11/2017)... 11, 2017 Crossmatch®, a globally-recognized leader ... today announced that it has been awarded a ... Activity (IARPA) to develop next-generation Presentation Attack Detection ... "Innovation has been a driving force within Crossmatch ... allow us to innovate and develop new technologies ...
Breaking Biology News(10 mins):